TrialAIDS (London, England)2026

Cardiometabolic impact of dolutegravir as second-line therapy: secondary analysis of a randomized controlled trial.

Phyo Pyae Nyein et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.